UNSPSC 51111830: Abiraterone

This classification denotes an anti-androgen with the molecular formula C24H31NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G819A456D0, chemically known as 17-(3-pyridyl)androsta-5,16-dien-3beta-ol but generally known as abiraterone, which bears US NIH Compound Identifier 132971. Abiraterone most often appears in forms base and acetate. European Medicines Agency schedules Abiraterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07361MIG.

UNSPSC 51111830 Abiraterone is a Commodity code covering pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure abiraterone and related generic pharmaceuticals through multistate cooperative contracting vehicles that consolidate demand across participating jurisdictions and establish master agreements with manufacturers for distribution through authorized pharmaceutical wholesalers. The solicitations under this code target manufacturers and pharmaceutical vendors capable of supplying products with specific National Drug Codes (NDCs), maintaining cGMP and Drug Supply Chain Security Act (DSCSA) compliance, and integrating with electronic data interchange (EDI) systems used by state purchasing offices and healthcare facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (S1070000015802) seeking multiple manufacturers for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The contract covers participating state and local government facilities across Minnesota and Oregon, with awarded vendors required to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and supply products with effective dates of July 1, 2026. Evaluation prioritizes price competitiveness (75 percent), fixed pricing for the contract term (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability insurance of $5,000,000 per occurrence and professional liability of $2,000,000, with contract terms of two years for new responders and extensions at MMCAP's discretion through June 30, 2028 for incumbents.